Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Study to Learn About Study Medicine Lorlatinib, as a First-line Treatment in Chinese Adults With ALK-positive a/mNSCLC
Sponsor: Pfizer
Summary
The purpose of this retrospective study is to learn about the real-world effects of the study medicine lorlatinib for the first-line treatment of Chinese adult patients who were diagnosed with ALK-positive a/mNSCLC. The participants included in this study are: * Aged 18 years or more * diagnosed with a/mNSCLC * confirmed with testing for ALK-positive * have started first-line lorlatinib treatment during the patient selection period In this study, the main objectives are to learn the patient characteristics and the real-world treatment pattern of first-line treatment of lorlatinib in China at a real-world setting.
Official title: Retrospective Chart Review Study of First Line Lorlatinib in Locally Advanced/Metastatic ALK-positive Non-Small Cell Lung Cancer Patients in China
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
OBSERVATIONAL
Enrollment
50
Start Date
2026-04-20
Completion Date
2026-06-30
Last Updated
2026-04-29
Healthy Volunteers
No
Conditions
Interventions
Lorlatinib
for the treatment of patients with locally advanced or metastatic ALK positive non-small cell lung cancer.